Blog

• Modos uses open hardware to fix everything wrong with sluggish commercial e-paper displays
• E-paper finally reaches 75Hz refresh rates, enough to handle modern productivity tasks
• USB Type-C and HDMI connectivity offer simple setup across Windows, macOS, and Linux

E-paper has is recent years often been relegated to niche applications, largely due to its sluggish refresh rates and limited interactivity.

However, Modos Tech is attempting to upend this perception with a new set of developer kits featuring e-paper displays capable of reaching 75Hz refresh rates, which are now crowdfunding.

Apple (the tech company ) vs Apple Corps (The Beatles’ record label) was one of the most epic trademark battles in history. The series of legal disputes lasted almost three decades, eventually leading Apple Computer to pay out $500 million to settle and acquire Apple Corps’ trademarks so it could use the name and logo for music distribution via iTunes.

A lot of people are now commenting on the apparent irony that now Apple is now suing Apple Cinemas for “knowingly and intentionally using the name Apple to sow confusion”. Apple doesn’t operate any cinemas and only started making films relatively recently. So is it all Apple and oranges?

Apple Cinemas is owned by Sand Media Corp Inc. It was founded in 2013 and now has 14 venues, identified by a logo that includes an apple shape formed by film. The chain was limited to the Northeastern US, but it’s now opened a cinema in San Francisco under 50 miles from Apple’s Cupertino headquarters and plans a nationwide expansion, which seems to be what sparked Apple to take action.

Smart locks offer better protection and peace of mind than traditional locks. They can also be great if you live alone and tend to forget your keys. After all, having the option to open your door using just your phone is pretty sweet.

We’ve spotted that the Lockly Flex Touch smart lock is now just $40 at SideDeal, which saves you a massive $140 over its usual asking price of $180. Its most advanced edition, the Lockly Flex Touch Pro, is one of our favorites. This Lockly Flex is a previous edition of Lockly’s current offerings and also has a lot of features to offer for its price range. You can also get free shipping when you use the coupon code FSDEALS at checkout.

The Lockly Flex Touch smart lock offers multiple options so you can open your doors, allow guests in and even use a key if you wish not to use smart features on a given day. The lock is easy for most people to install and allows you to unlock your key with a biometric fingerprint, your phone or your regular key. You can also assign up to 99 fingerprints, which makes this lock a great option for small businesses or offices. When our experts tested this smart lock, they appreciated the functionality, but their only concern was the steep price, which thankfully, this deal takes care of.

Hey, did you know? CNET Deals texts are free, easy and save you money.

To work properly, the Lockly Flex Touch smart lock needs four AA batteries and it automatically locks behind you once you enter your destination. Batteries can last up to 10 months with consistent use, and you can use a 9-volt battery to temporarily open your door should your AA batteries run out of power. Your purchase also includes everything you need to properly install this lock to your door.

If you need to research more options, check out our smart lock buying guide, which outlines everything you need to know to find the right smart lock for your needs.

Why this deal matters

Smart locks are a small one-time purchase that adds loads of security to your home and makes it easier to avoid getting locked out. With its capacity for up to 99 fingerprint assignments, the Lockly Flex Touch smart lock is a great way to allow guests, frequent visitors or even employees into your home or small business without having to worry about keeping track of keys. The $40 price saves you a massive $140, which means now is a great time to nab this deal.

An analysis of healthy adult participants from a phase 1 trial showed that treatment with ACP-204 (Acadia Pharmaceuticals), a selective inverse agonist/antagonist of serotonin 2A (5-HT2A) being developed for Alzheimer disease psychosis (ADP), led to no meaningful increases in Friderica-corrected QT (ΔQTcF) intervals.¹

Presented at the 2025 Alzheimer’s Association International Conference (AAIC), held July 27-31 in Toronto, Canada, the analysis comprised 57 healthy adults to test corrected QT (QTc) intervals in single ascending oral doses of ACP-204 (10 to 180 mg) vs placebo. All told, the QTcF interval did not exceed 450 ms at any time point for any participant, and no dose-response pattern was observed. In addition, the Friderica heart rate correction met adequacy criteria, as 89.5% of participants had QTcF versus RR interval slopes <|0.045|, exceeding the 50% requirement.

QT interval prolongation is a known adverse event of many psychotropic medications because of their ability to modulate neurotransmitters. These same neurotransmitters can influence cardiac ion channels, particularly the hERG potassium channel, which is key for QT interval regulation. From a regulatory standpoint, a finding of QTcF prolongation greater than 500 ms, or changes greater than 60 ms from baseline, may lead to dose restriction, additional studies, or program discontinuation.

Led by Mona Darwish, PhD, senior director of clinical pharmacology at Acadia, a ΔQTcF of at least 30 ms and less than 60 ms was observed in 1 participant in each of the 60, 130, and 180 mg cohorts. In addition, there was one participant in the 40 mg cohort who had ΔQTcF exceed 60 ms. Overall, the changes observed using concentration-effect modeling were small and benign, with no QTcF prolongation up to 180 mg.

After subtracting the placebo ΔQTcF, the upper limit of the confidence band remained below 10 ms throughout to the maximum observed concentration of around 395 ng/mL. All told, model-predicted average placebo-adjusted ΔQTcF (ΔΔQTcF) at mean Cmax levels for all dose cohorts ranged from 3.17 ms (10 mg) to 0.47 ms (180 mg). In addition, the upper limit of the 2-sided 90% CI for ΔΔQTcF at 180 mg was 6.51 ms.

READ MORE: Targeting SIGLEC10 With ONC-841: A Novel Mechanism in Alzheimer Disease Treatment

A second presentation at AAIC 2025 looked at the effect of food consumption on the pharmacokinetics of ACP-204. This single-center, randomized, open-label, crossover, phase 1 trial included 36 healthy participants who received 60 mg dose of ACP-204, with pharmacokinetic sampling occurring on days 1-6 after drug administration. Overall, the 90% CI for the geometric mean ratio of fasted to fed for AUC_0‑∞ (GMR = 115.18%), AUC_0-t (GMR = 115.03%), and C_max (GMR = 101.89%) fell within the bioequivalence limits (80% to 125%).²

Overall, these results indicated that food has no effect on the extent of ACP-204 absorption, and minimal effect on the absorption rate, which was slightly delayed (~3 h) under fed (T_max = 8.98 hours) vs fasted (T_max = 5.98 hours) conditions. In terms of safety, there were 4 (11.1%) drug-related treatment-emergent adverse events (TEAEs), with no serious TEAEs and no AEs leading to death or discontinuation.

An investigational agent, ACP-204 works primarily as an inverse agonist at the 5-HT_2A receptor, building upon the learnings of pimavanserin (Nuplazid), Acadia’s FDA-approved medication for patients with Parkinson disease psychosis. In November 2023, Acadia began a phase 2/3 program, with its initial phase 2 trial testing the efficacy and dose response of 6 weeks of 30 or 60 mg ACP-204, or placebo, in approximately 1074 patients with ADP.

The phase 2 study, which has yet to have data read out, uses change in the Scale for the Assessment of Positive Symptoms–Hallucinations and Delusions subscales as the primary end point, while clinician-rated improvement in symptoms served as a secondary end point. Based on the results, two phase 3 studies, currently registered, will each enroll 378 patients with ADP, for 6 weeks of treatment at 1 or both doses, against the same end points. Patients who complete the study will have the option of enrolling in a long-term open-label extension, expected to conclude in 2028.³

Click here for more AAIC 2025 coverage.

REFERENCES
1. Darwish M, Mason JW, Stanworth SW, et al. Analyzing the Effect of ACP-204 on the QTc Interval in Healthy Adult Participants Using Phase 1 Study Data. Presented at: AAIC 2025; July 27-31; Toronto, Canada. ABSTRACT 105893
2. Darwish M, Dirks B, Feng X, et al. Effect of Food Consumption on the Pharmacokinetics of ACP-204, a Novel 5-HT2A Receptor Selective Antagonist/Inverse Agonist. Presented at: AAIC 2025; July 27-31; Toronto, Canada. ABSTRACT 105644
3. ACP-204. Alzforum. https://www.alzforum.org/therapeutics/acp-204. Updated February 5, 2024. Accessed August 7, 2025.